Two new drugs approved in the last week:
1. sotorasib, a drug for a specific KRAS mutation (G12C) in 2nd line metastatic NSCLC
2. infigratinib, basically a "me too" FGFR inhibitor approved for metastatic cholangiocarcinoma

We all discuss the latest adjuvant CHECKMATE study (nivolumab in urothelial carcinoma) and a recent study of seropositivity in cancer patients following COVID vaccination.

ASCO 2021

OncoPharm is a podcast dedicated to all things oncology pharmacy.  Most episodes cover updates and recent publications concerning the use of medications in caring for patients we cancer.  Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.